The healthcare organizations in China are acquiring companies in the biotechnology, health-care and pharmaceutical sectors to consolidate their position in the global healthcare markets. Chinese organizations have spent over 3.9 billion dollars in their bid to acquire firms on an international level. With this move, China managed to surpass previous year’s acquisition record. This figure was also ten times higher in comparison to the total amount spent for acquisition in 2012. It must be noted that this sudden increase in acquisition figures came in the wake of the decision taken by Chinese companies to diversify into global markets as well as the government’s resolve to popularize the Chinese brand of products and goods.
Financial experts and specialists pointed out that success in the global markets would enable the Chinese firms to enhance their existing portfolios and identify newer expansion areas. Additionally, it would also provide them with an opportunity to enter into the developed countries having stringent regulations and standards.